Health care reform is likely this year. How will that affect your pharma investments?
The man who might replace the king writes about his own business principles and strategies.
A cardiologist examines the Enhance trial results.
More bad news for Vytorin.
More and more, they're popping up overseas.
... Congress and the FDA listen.
How young? One visitor to the Berkshire Hathaway meeting isn't old enough for a paper route.
New study results could affect stent sales -- at least in the short term.
Will Chantix help Pfizer cure its ailing stock price?
One of the bedrock principles of our economic system is that those buying more of a product receive a discount.
The very nature of the pharmaceutical business makes valuing such companies difficult.
In "surprising and disappointing" news, its promising new drug fails clinical trials.
The merger says a lot about companies that sell pharmaceuticals trying to deal with a rapidly changing paradigm.
One study could boost the stock of a company with a special machine for heart patients.
New data suggesting problems with drug-eluting stents may translate into more sales of the blood thinner and fewer sales of the stents.
Medicare law changes may drive the amount that hospitals can pay for pacemakers.
Celebrex is still shown to increase the risk of heart problems, but that might not be bad news for Pfizer shareholders.
Wal-mart's $4 generic-drug program could be the start of big changes in the $250 billion prescription-drug market.